Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Fuji
Chinese Patent Office
McKesson
Covington
UBS
Deloitte
US Department of Justice
Cerilliant

Generated: July 16, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,241,805

« Back to Dashboard

Which drugs does patent 7,241,805 protect, and when does it expire?

Patent 7,241,805 protects APLENZIN and is included in one NDA.

This patent has forty-nine patent family members in seventeen countries.
Summary for Patent: 7,241,805
Title:Modified release formulations of a bupropion salt
Abstract:The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.
Inventor(s): Oberegger; Werner (Mississauga, CA), Zhou; Fang (Davie, FL), Maes; Paul (Toronto, CA), Turchetta; Stefano (Rome, IT), Jackson; Graham (Kildare, IE), Massardo; Pietro (Rome, IT), Saleh; Mohammad Ashty (Oakville, CA)
Assignee: Biovail Laboratories, Inc. (Mississauga, Ontario, CA)
Application Number:11/475,252
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,241,805
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Dosage form; Use;

Drugs Protected by US Patent 7,241,805

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Valeant Pharms North APLENZIN bupropion hydrobromide TABLET, EXTENDED RELEASE;ORAL 022108-001 Apr 23, 2008 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Valeant Pharms North APLENZIN bupropion hydrobromide TABLET, EXTENDED RELEASE;ORAL 022108-002 Apr 23, 2008 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Valeant Pharms North APLENZIN bupropion hydrobromide TABLET, EXTENDED RELEASE;ORAL 022108-003 Apr 23, 2008 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,241,805

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,671,094 Bupropion hydrobromide and therapeutic applications ➤ Try a Free Trial
7,572,935 Modified release formulations of a bupropion salt ➤ Try a Free Trial
7,579,380 Modified release formulations of a bupropion salt ➤ Try a Free Trial
7,553,992 Modified release formulations of a bupropion salt ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 7,241,805

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Singapore 183695 ➤ Try a Free Trial
Russian Federation 2485943 ➤ Try a Free Trial
Russian Federation 2010107843 ➤ Try a Free Trial
Russian Federation 2485942 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Chubb
Queensland Health
Express Scripts
Merck
UBS
Fuji
Federal Trade Commission
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.